 Wall Street Journal |
Glaxo Tries to Shake Marketing Questions on Advair
Wall Street Journal GlaxoSmithKline's $3 billion criminal and civil settlement with the U.S. government this week raises questions about the future of asthma treatment Advair. Glaxo Executives Cited in Case Now Lead Sanofi, Actelion WSJ: Glaxo Tries to Shake Marketing Questions Ex-Glaxo execs in U.S. case now lead other drugmakers |
View full post on asthma – Google News